The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review
- 20 November 2025
- journal article
- review article
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (1) , 197-210
Abstract
BACKGROUND: Adaptive and master protocol clinical trials offer significant advantages for diabetes research, including enhanced efficiency and personalized treatment strategies. PURPOSE: This scoping review aimed to systematically map the use of adaptive and master protocol designs in interventional trials for type 1 and type 2 diabetes, identify research gaps, and highlight opportunities for broader implementation. DATA SOURCES: A systematic literature search was performed using MEDLINE, Embase, CENTRAL, Emcare, Global Health, Web of Science, and clinical trial registries. Gray literature searches complemented database findings. STUDY SELECTION: Studies using adaptive, platform, basket, or umbrella trial designs in people with type 1 or type 2 diabetes were included. DATA EXTRACTION: Data were charted using a standardized form. Extracted variables included diabetes type, trial design, adaptive features, interventions, end points, and key findings. DATA SYNTHESIS: Of 396 articles screened, 6 published adaptive trials met the inclusion criteria: 3 in type 1 diabetes, 1 in type 2 diabetes, and 2 in diabetes-related neuropathy. Most used adaptive features for dose finding, response-adaptive randomization, and sample size reestimation. No published platform, basket, or umbrella trials were identified. Six ongoing adaptive trials in type 1 diabetes were identified through registry searches, four under an adaptive platform master protocol. LIMITATIONS: Despite a comprehensive search, some gray literature and unpublished studies may have been missed. Risk of bias was not assessed, consistent with scoping review methodology. CONCLUSIONS: Adaptive and master protocol trials remain rare in diabetes. Overcoming barriers through targeted training and awareness, robust regulatory frameworks, and strategic incentives could support broader adoption.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic PainJAMA Network Open, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Continuous glucose monitoring and metrics for clinical trials: an international consensus statementThe Lancet Diabetes & Endocrinology, 2022
- A systematic review and meta-analysis to compare the prevalence of depression between people with and without Type 1 and Type 2 diabetesPrimary Care Diabetes, 2022
- Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical TrialTherapeutic Innovation & Regulatory Science, 2020
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- Real-world studies no substitute for RCTs in establishing efficacyThe Lancet, 2019
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variablesThe Lancet Diabetes & Endocrinology, 2018
- Late-stage research for diabetes and related NCDs receives little funding: evidence from the NIH RePORTER tool.The Lancet Diabetes & Endocrinology, 2016
- Blinded Sample Size Reestimation in Non‐Inferiority Trials with Binary EndpointsBiometrical Journal, 2007